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Effects of atypical antipsychotic drugs on QT interval in patients 
with mental disorders
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Background: Drug-induced QT prolongation is associated with higher risk of cardiac arrhythmias and 
cardiovascular mortality. We investigated the effects of atypical antipsychotic drugs on QT interval in 
children and adults with mental disorders.
Methods: We conducted random-effects direct frequentist meta-analyses of aggregate data from 
randomized controlled trials (RCT) and appraised the quality of evidence using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) methodology. Our search 
in PubMed, EMBASE, the Cochrane Library, clinicaltrials.gov, and PharmaPendium up to October 
2017 identified studies that examined aripiprazole, quetiapine, risperidone, olanzapine, ziprasidone and 
brexpiprazole.
Results: Low quality evidence suggests that aripiprazole (four meta-analyses and twelve RCTs), 
brexpiprazole (one systematic review and four RCTs) or olanzapine (five meta-analyses and twenty RCTs) do 
not increase QT interval. Low quality evidence suggests that ziprasidone (five meta-analyses and 11 RCTs) 
increases QT interval and the rates of QT prolongation while risperidone (four meta-analyses, 70 RCTs) and 
quetiapine (two meta-analyses and seven RCTs) are associated with QT prolongation and greater odds of 
torsades de pointes ventricular tachycardia especially in cases of drug overdose. 
Conclusions: The main conclusion of our study is that in people with mental disorders and under 
treatment with atypical antipsychotic drugs, in order to avoid QT prolongation and reduce the risk of 
ventricular tachycardia clinicians may recommend aripiprazole, brexpiprazole or olanzapine in licensed 
doses. Long-term comparative safety needs to be established.
Keywords: Quality of evidence; cardiovascular morbidity; drug-induced QT prolongation; aripiprazole; 
quetiapine; risperidone; olanzapine; ziprasidone; brexpiprazole
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Introduction
Observational studies provide consistent evidence that 
prolonged QT interval is associated with higher risk of 
all-cause and cardiovascular mortality (1). Drug-induced 
prolongation of QT contributes to higher mortality (2,3). 
The risk of drug-induced prolongation of QT is much 
higher in older adults and people with multiple chronic 
conditions (4). Psychotropic drugs including atypical 
antipsychotic agents are commonly prescribed for licensed 
and off-label indications and may contribute to the higher 
risk of drug-induced QT prolongation (5,6). This rapid 
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review focuses on the effects of atypical antipsychotic 
drugs on QT interval in children and adults with mental 
disorders.
Methods
We used a standard recommended methodology in 
conducting systematic literature reviews and meta-analyses 
from the Cochrane Collaboration and the Agency for 
Healthcare Research and Quality (7,8). We developed 
a priori protocol for a systematic literature review to 
answer the clinical question about the safety of atypical 
antipsychotic drugs on QT interval in children and adults 
with mental disorders.
We defined the target population as people with mental 
disorders treated with atypical antipsychotic drugs. Eligible 
interventions included atypical antipsychotics when 
compared with placebo or other antipsychotic medications. 
Eligible outcomes included change in QT Interval, 
clinically important prolongation of QT corrected to RR 
interval ≥450 msec in men ≥480 msec in women, and QTc 
≥500 msec associated with increased risk of life-threatening 
torsades de pointes ventricular tachycardia (9).
We conducted a comprehensive search in PubMed, 
EMBASE, the Cochrane Library, www.clinicaltrials.gov 
and PharmaPendium (www.pharmapendium.com) up to 
October 2017 to find systematic reviews, published and 
unpublished RCTs, and nationally represented controlled 
observational studies that reported adjusted effect estimates 
(7,8). All of the authors determined the studies’ eligibility. 
All citations found during the searches are stored in a 
reference database. 
The data was extracted from the Clinical Trials 
Transformation Initiative (CTTI) (https://www.ctti-
clinicaltrials.org/aact-database), checked for quality, 
and stored in the HPCC platform (High-Performance 
Computing Cluster, https://hpccsystems.com/). 
We performed direct frequentist meta-analyses of 
aggregate data when definitions of the active and control 
intervention and patient outcomes were deemed similar 
for pooling (10). We used random effects models to 
address inevitable differences in patient characteristics 
across primary RCTs. For each abstracted hypothesis, we 
calculated absolute risk difference and relative risk with 
95% CI. We calculated number needed to treat and number 
of attributable events per 1,000 treated with 95% CI based 
on statistically significant differences in absolute risks of 
the outcomes. We examined consistency in results across 
studies with chi-square tests and I2 statistics and concluded 
statistically significant heterogeneity if I2 was >50% (7). 
Statistically significant heterogeneity did not preclude 
statistical pooling (10). However, we planned exploring 
heterogeneity with a priori defined patient characteristics, 
drug doses, and study quality if this information was 
available in the studies (10).
We used consensus method guidelines for systematic 
review and meta-analyses that do not recommend 
conducting post hoc analyses of statistical power (11-14). 
Instead, we downgraded our confidence in true treatment 
effects based on calculated optimal information size as the 
number of patients required for an adequately powered 
individual trial (15). Since power is more closely related 
to number of events than to sample size, we concluded 
imprecision in treatment effects if fewer than 250 patients 
experienced the event (15).
We used Statistics/Data Analysis, STATA software 
(StataCorp LP, College Station, Texas). Statistical 
significance was evaluated at a 95% confidence level.
We evaluated the quality of systematic reviews using the 
Assessment of Multiple Systematic Reviews (AMSTAR) (16). 
For primary RCTs, we used the Cochrane risk of bias tool 
on a 3-point scale: high bias, low bias, and unclear (17,18). 
A low risk of bias was assumed when RCTs met all the risk-
of-bias criteria, a medium risk of bias if at least 1 of the risk-
of-bias criteria was not met, and a high risk of bias if two or 
more risk-of-bias criteria were not met. An unknown risk 
of bias was assigned for the studies with poorly reported 
risk-of-bias criteria. We assigned high risk of bias to all 
observational studies.
The authors assigned the quality of evidence ratings as 
high, moderate, low, or very low, according to risk of bias in 
the body of evidence, directness of comparisons, precision 
and consistency in treatment effects, and the evidence 
of reporting bias, using Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
methodology (19). 
A high quality of evidence was assigned to well-designed 
RCTs with consistent findings. The quality of evidence 
was downgraded to moderate if at least 1 of 4 quality of 
evidence criteria was not met; for example, moderate quality 
of evidence was assigned if there was a high risk of bias in 
the body of evidence or if the results were not consistent 
or precise. The quality of evidence was downgraded to low 
if two or more criteria were not met. We concluded a high 
risk of bias in the body of evidence if at least one RCT had 
high risk of bias. We downgraded the quality of evidence 
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when we suspected high risk of publication bias due to 
unavailability of the results in clinicaltrials.gov or journal 
articles.
A low quality of evidence was assigned to nonrandomized 
studies, but the rating was upgraded if there was a 
strong or dose-response association (20). Evidence was 
defined as insufficient when no studies provided valid 
information about treatment effects. This approach was 
applied regardless of whether the results were statistically 
significant.
Results
Our comprehensive search in PubMed, EMBASE, the 
Cochrane Library, and clinicaltrials.gov up to May 2017 
identified clinical studies that examined aripiprazole, 
quetiapine, risperidone, olanzapine, ziprasidone or 
brexpiprazole.
  Risperidone was examined in three systematic reviews 
and meta-analyses, one individual patient data network 
meta-analysis of 64 RCTs, published and unpublished data 
from six RCTs and six non-randomized studies (21-40).
Evidence suggests that risperidone is associated with 
QT prolongation in children and adolescents with mental 
disorders (Table 1).
A single industry-sponsored individual patient meta-
analysis of 64 RCTs suggests that risperidone results in QT 
prolongation when compared with placebo in adults with 
mental disorders (Table 1). The evidence from the FDA 
Adverse Event Reporting System database suggests that 
risperidone is associated with greater odds of torsades de 
pointes ventricular tachycardia in adults with indication 
for antipsychotics (Table 1). Industry—sponsored post-
marketing analysis suggests that all cases of ventricular 
tachycardia have been associated with overdose of 
risperidone (41).
The direct evidence of comparative safety between 
risperidone and other antipsychotics is sparse. Risperidone 
is associated with QT abnormalities when compared with 
aripiprazole in pediatric patients with mental disorders and 
concomitant use of stimulants (Table 2). Some evidence 
suggests that there are no differences in QT abnormalities 
or rates of torsades de pointes between risperidone and 
atypical antipsychotics or haloperidol in adults with mental 
disorders (Table 2). A single RCT suggests that risperidone 
decreases QT interval when compared with ziprasidone 
(Table 2).
Post-marketing surveillance suggests 43 cases of 
prolonged QT intervals and 71 cases of torsades de pointes 
tachycardia in people treated with risperidone among other 
medications for various mental disorders (Table S1).
  Ziprasidone was examined in four systematic reviews 
and meta-analyses, one industry sponsored individual 
patient data network meta-analysis and published and 
unpublished data from 11 RCTs and three non-randomized 
trials (30,35,37,38,42-56).
Evidence suggests that ziprasidone increases QT 
interval and the rates of QT prolongation by >30 msec 
when compared with placebo (Table 3) or haloperidol 
(Table 4) in people with mental disorders. Ziprasidone also 
prolongs QT interval when compared with olanzapine 
and risperidone (Table 5). There are no differences in the 
length of QT interval after treatment with ziprasidone 
versus aripiprazole (Table 5). Chlorpromazine increases the 
duration of QT interval when compared with ziprasidone 
(Table 5). 
Available studies did not report the rates of torsade 
de pointes ventricular tachycardia in adults treated with 
ziprasidone. Post-marketing observational study suggested 
no differences in mortality after 1-year treatments with 
ziprasidone versus olanzapine in 18,154 adults with 
schizophrenia (Table S2). Post-marketing surveillance 
identified 202 cases of prolonged QT interval and 83 cases 
of torsade de pointes in patients treated with ziprasidone 
among other drugs (Table S1).
The evidence is applicable mostly to adults. Pediatric 
studies reported no events of QT prolongation after 
higher (160 mg/day) or lower (20 mg/d titrated to between 
80 mg/day) doses on ziprasidone (37,42).
  Olanzapine was examined in four systematic reviews 
and meta-analyses and one individual patient data network 
meta-analysis. (35,37,38,57,58). We also identified published 
and unpublished data from 20 RCTs and 1 non-randomized 
trial (30,43,59-79).
Available low-quality evidence suggests that olanzapine 
has no effect on QT interval when compared with placebo 
in children and adolescents with mental disorders (Table 6). 
We also found that that oral olanzapine has no effect on 
QT interval while intramuscular olanzapine decreases QT 
interval when compared with placebo in adults with mental 
disorders (Table 6).
A single small RCT suggests that there are no differences 
in QT interval between olanzapine and haloperidol 
in children and adolescents with autistic disorder 
(Table 7). Moderate quality evidence suggests that there 
are no differences in QT interval between olanzapine and 
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Table 2 Risperidone versus active comparators on QT interval in people with mental disorders
Outcome
Risk with intervention 
per 1,000 
Risk with comparator 
per 1,000
Relative measure of 
association 
Number of 
participants (studies)
Quality 
(GRADE)
Comments†
Risperidone versus aripiprazole in children and adolescents 
QTc, msec, >18 months NR NR MD −1.20 (−8.94, 
6.54); SMD −0.06 
(−0.46, 0.33)
99 (prospective 
analysis registry*) (23)
Very low No difference
QTc >450 msec, or QTc 
prolongation >60 msec, 
or QTc dispersion 
>100 msec; subgroup: 
concomitant stimulant
NR NR Adjusted OR 4.23 
(1.10, 17.00)
99 (prospective 
registry analysis*) (23)
Very low Favors 
aripiprazole
QTc >500 msec 0 0 RR undetermined 99 (prospective 
analysis registry*) (23)
Very low No difference
Risperidone long-acting Injection versus oral atypical antipsychotics (olanzapine, quetiapine, aripiprazole or amisulpride) in adults
QT prolonged 0 11 RR 0.35 (0.01, 8.56) 167 (1 RCT) (39) Very low No difference
Risperidone or paliperidone versus active control in adults
Torsades/QT 
prolongation
18 19 RR 0.94 (0.59, 1.51) 7,573 (64 RCTs) (21) Very low No difference
Risperidone 16 mg/d versus haloperidol 15 mg/d in adults
QTc >500 msec 0 0 RR Undetermined 52 (1 RCT) (30,38) Very low No difference
Risperidone 4 mg versus risperidone, 2 mg/d + Haloperidol, 2 mg/d in adults
QTc, msec NR NR MD −1.49 (−14.77, 
11.79); SMD −0.06 
(−0.57, 0.46)
58 (1 RCT) (28,29) Very low No difference
Risperidone versus olanzapine in adults
Torsades de Pointes, 
sudden cardiac death
NR NR Adjusted HR 1.04 
(0.88, 1.24)
459,614  
(1 observational study 
of medicaid database) 
(33)
Very low No difference
Risperidone versus ziprasidone in adults
QTc NR NR MD −21.80 (−28.13, 
−15.47); SMD −2.76 
(−3.90, −1.62)
24 (1 RCT) (26,27) Very low Favors 
risperidone
*, SafEty of NeurolepTics in Infancy and Adolescence (SENTIA) registry (https://sentia.es). †, we concluded that there is no difference 
in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without post-
hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations 
Assessment, Development and Evaluation; OR, odds ratio; NNT, number needed to treat to achieve an outcome in one patient; NNT is 
calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1000 
treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by 
1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention 
and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard 
deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported.
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haloperidol, asenapine, or lorazepam in adults with mental 
disorders (Table 7). Intramuscular olanzapine decreases QT 
interval when compared with haloperidol in agitated adults 
(Table 7).
Post-marketing surveillance suggests 84 cases of 
prolonged QT intervals and 53 cases of torsades de pointes 
tachycardia in people treated with olanzapine among other 
medications for various mental disorders (Table S1).
Quetiapine was examined in two systematic reviews and 
meta-analyses (38,80). We also identified published and 
unpublished data from 7 RCTs and 4 non-randomized 
studies (21-40,81-86).
When compared with placebo or no active treatment, 
evidence suggests that quetiapine is not associated with 
the risk of QT prolongation in children and adolescents 
(Table 8). In contrast, quetiapine is associated with higher 
odds of torsade’s de pointes or QT interval abnormalities in 
adult patients with mental disorders (Table 8).
When compared with other antipsychotics, sparse 
evidence suggests that there are no differences in QT 
interval between quetiapine and haloperidol or risperidone 
(Table 9). Sparse data from a single RCT suggests that 
quetiapine decreases QT interval when compared with 
ziprasidone in adults with mental disorders (Table 9). 
Observational analysis of Medicaid database demonstrates 
that quetiapine is associated with the lower risk of torsade’s 
de pointes or sudden cardiac death when compared with 
olanzapine (Table 9).
Post-marketing surveillance suggests 56 cases of 
prolonged QT intervals and 90 cases of torsade’s de pointes 
tachycardia in people treated with olanzapine among other 
medications for various mental disorders (Table S1).
Aripiprazole was examined in four systematic reviews 
and meta-analyses and published and unpublished 
data from 12 RCTs and three non-randomized trials 
(35-37,60-62,87-97). 
Evidence suggests that there are no differences in QT 
interval changes or rates of prolonged QT interval between 
aripiprazole and placebo, risperidone or haloperidol in 
adults with mental disorders (Table 10). Higher dose of 
aripiprazole does not increase QT interval when compared 
with the lower dose (Table 10). Available studies did not 
report the rates of torsade de pointes ventricular tachycardia 
in adults treated with aripiprazole. Post-marketing 
surveillance identified 15 cases of prolonged QT interval 
and 21 cases of torsade de pointes in patients treated with 
aripiprazole among other drugs (Table S1).
Sparse evidence suggests that aripiprazole is associated 
with reduction in QT interval in pediatric patients with 
mental disorders (Table 11). Sparse evidence suggests that 
there are no differences in the rates of prolonged QT 
interval between aripiprazole, placebo, risperidone or 
pimozide in children and adolescents with mental disorders 
(Table 11).
The evidence regarding the role of chronic inflammation 
or genetic polymorphism on QT interval in patients taking 
aripiprazole is insufficient (98-100).
Aripiprazole may present a safer choice in patients who 
need antipsychotic drugs and have no cardiac disorders 
associated with higher risk of cardiac death (101).
Brexpiprazole was examined in one systematic review and 
unpublished data from four RCTs (102-105).
Evidence suggests that there are no differences in the 
rates of the prolonged (>500 msec or increase by >60 msec) 
QT interval between brexpiprazole and placebo in adults 
with mental disorders (Table 12). Sparse evidence from a 
single unpublished RCT suggests that the lower (4 mg) 
but not higher (12 mg) dose of brexpiprazole prolongs 
QT interval when compared with placebo (Table 12). 
The evidence regarding effects of brexpiprazole on QT 
interval in children is insufficient. The evidence regarding 
comparative safety between brexpiprazole and other 
antipsychotics on QT interval or the risk of ventricular 
tachycardia is insufficient.
Post-marketing surveillance does not detect cases of 
prolonged QT intervals or torsades de pointes tachycardia 
in people treated with brexpiprazole among other 
medications for various mental disorders (Table S1).
Discussion
Our review of clinical trials, observational studies and post-
marketing surveillance found mostly low quality of evidence 
concerning higher risk of antipsychotic drugs induced QT 
prolongation. In people with mental disorders referred for 
treatment with atypical antipsychotic drugs, in order to 
avoid QT prolongation and reduce the risk of ventricular 
tachycardia clinicians may recommend aripiprazole, 
brexpiprazole or olanzapine in licensed doses. 
Our findings are in concordance with previously 
published observational studies that reported a positive 
association between antipsychotic drugs and the increased 
risk of cardiac arrest (106-108).
We downgraded the quality of evidence due to the 
high risk of bias and small number of events in the RCTs. 
The majority of clinical studies did not have statistical 
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power to detect higher risk of ventricular tachycardia. 
We further downgraded the quality of evidence due to 
reporting bias because very small proportion of primary 
studies that examined benefits of atypical antipsychotics also 
examined drug-induced QT prolongation. Retrospective 
post-marketing case reports collection is biased because 
the reporting depends on clinician opinion regarding 
the association between ventricular tachycardia and 
administration of antipsychotic drugs (109). 
Available industry guidelines recommend intensive 
ECG monitoring of QT intervals in clinical trials 
of non-antiarrhythmic drugs with suspected pro-
arrhythmic potential but do not require proactive post-
marketing monitoring in real-life settings (110). Some 
clinical guidelines recommend careful consideration of 
individual benefits and harms including drug-induced 
QT prolongation in people with mental disorders and 
indication for antipsychotic drugs (111-113). Only two 
British guidelines and one US guideline meet 2013 
Institute of Medicine criteria for trustworthy guidelines 
(111-113). Drug labels recommend against administration of 
quetiapine or ziprasidone in combination with other drugs 
that are known to prolong QT interval and in people with 
bradycardia, hypokalemia or hypomagnesemia, congenital 
prolongation of the QT interval (114,115). Despite these 
recommendations, prevalence of polypharmacy with 
multiple pro-arrhythmic drugs is high (2,4,101). 
Our review has implications for clinical practice. 
Clinicians should evaluate baseline risk for cardiac 
arrhythmias before offering atypical antipsychotic 
drugs (116). Routine ECG monitoring for the prolongation 
of QT interval should be recommended for all patients 
under the treatment with atypical antipsychotic drugs (117). 
Multidisciplinary coordinated care should be practiced to 
avoid polypharmacy with multiple pro-arrhythmic drugs 
(116,118). Patients should be proactively examined for clinical 
symptoms indicating the occurrence of cardiac arrhythmias, 
e.g., dizziness, palpitations, or syncope (119). Our review 
has policy implications. Prescribing quality in compliance 
with licensed drug use should be routinely evaluated 
with electronic decision support systems. (114,115,120). 
Proactive technologically advanced pharmacovigilance 
applications should be implemented to decrease the risk of 
drug-induced QT prolongation and cardiac arrhythmias 
(109,121-124).
Our review has research implications. Future proactive 
post-marketing surveillance should examine long-term 
comparative safety of atypical antipsychotic drugs in 
patients with different age, primary diagnosis and multiple 
comorbidities and concomitant drugs. Novel technology 
applications and adequate statistical methods should be 
used for routine analysis of antipsychotic-induced QT 
prolongation and cardiac arrhythmias. 
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Table S1 Post-marketing reports of adverse effects associated with antipsychotics (from PharmaPendium.com)
Drug Adverse effects [case] Gender [case] Age [case]
Risperidone Torsade de pointes [71] Female [38], Male [26] 20+ [49], <20 [2]
Risperidone Electrocardiogram QT corrected interval prolonged [43] Female [23], Male [20] 20+ [26], <20 [4]
Ziprasidone 
Hydrochloride
Torsade de pointes [83] Female [61], Male [19] 20+ [57]
Ziprasidone 
Hydrochloride
Electrocardiogram QT corrected interval prolonged [202] Female [117], Male [63] 20+ [129], <20 [22]
Olanzapine Torsade de pointes [54] Female [32], Male [19] 20+ [51]
Olanzapine Electrocardiogram QT corrected interval prolonged [84] Female [48], Male [26] 20+ [61], <20 [6]
Quetiapine Torsade de pointes [90] Female [68], Male [14] 20+ [79], <20 [1]
Quetiapine Electrocardiogram QT corrected interval prolonged [56] Female [28], Male [24] 20+ [39], <20 [9]
Aripiprazole Torsade de pointes [21 cases] Female [12], Male [6] 20+ [15], <20 [2]
Aripiprazole Electrocardiogram QT corrected interval prolonged [15 cases] Female [6], Male [6] 20+ [6], <20 [4]
Supplementary
Table S2 Mortality and hospitalization in 18,154 adults with schizophrenia treated with ziprasidone or olanzapine [crude results from the 
Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)] 
Outcome
Risk with intervention 
per 1,000 
Risk with comparator 
per 1,000
Relative measure of 
association 
Quality 
(GRADE)
Comments
Non-suicide mortality, 1 year 9 9 RR 1.02 (0.76, 1.39) Very low No difference
All-cause mortality, 1 year 11 11 RR 1.01 (0.77, 1.33) Very low No difference
Cardiovascular mortality, 1 year 0 1 RR 0.38 (0.10, 1.41) Very low No difference
Mortality due to suicide, 1 year 2 2 RR 1.19 (0.61, 2.31) Very low No difference
Sudden death, 1 year 0 0 RR 0.67 (0.11, 3.99) Very low No difference
Hospitalization, all-cause, 1 year 151 109 RR 1.39 (1.29, 1.50) Low Favors 
olanzapine
Hospitalization, arrhythmia, 1 year 1 0 RR 1.75 (0.51, 5.98) Very low No difference
Hospitalization, myocardial infarction, 
1 year
1 1 RR 1.18 (0.53, 2.64) Very low No difference
Hospitalization, diabetic ketoacidosis, 
1 year
1 1 RR 1.00 (0.29, 3.45) Very low No difference
